Influence of the HCV Subtype on the Virological Response to Pegylated Interferon and Ribavirin Therapy

被引：43

作者：

Legrand-Abravanel, Florence ^{[1
]}

Colson, Philippe ^{[2
]}

Leguillou-Guillemette, Helene ^{[3
]}

Alric, Laurent

Ravaux, Isabelle ^{[4
]}

Lunel-Fabiani, Francoise ^{[3
]}

Bouviers-Alias, Magali ^{[5
]}

Trimoulet, Pascale ^{[6
]}

Chaix, Marie Laure ^{[7
]}

Hezode, Christophe ^{[8
]}

Foucher, Juliette ^{[9
]}

Fontaine, Helene ^{[10
]}

Roque-Afonso, Anne-Marie ^{[11
]}

Gassin, Michele ^{[12
]}

Schvoerer, Evelyne ^{[13
]}

Gaudy, Catherine ^{[14
]}

Roche, Bruno ^{[15
]}

Doffoel, Michel ^{[16
]}

D'Alteroche, Louis ^{[17
]}

Vallet, Sophie ^{[18
]}

Baazia, Yazid ^{[19
]}

Pozzetto, Bruno ^{[20
]}

Thibault, Vincent ^{[21
]}

Nousbaum, Jean-Baptiste ^{[22
]}

Roulot, Dominique ^{[23
]}

Coppere, Henry ^{[24
]}

Poinard, Thierry ^{[25
]}

Payan, Christopher ^{[22
]}

Izopet, Jacques ^{[1
]}

机构：

[1] Ctr Hosp Univ, Virol Lab, Toulouse, France

[2] Ctr Hosp Univ, Virol Lab, Marseille, France

[3] Ctr Hosp Univ, Virol Lab, Angers, France

[4] Ctr Hosp Univ, Serv Malad Infect, Marseille, France

[5] CHU Henri Mondor, Virol Lab, F-94010 Creteil, France

[6] Ctr Hosp Univ, Virol Lab, Bordeaux, France

[7] CHU Necker, Virol Lab, Paris, France

[8] CHU Henri Mondor, Serv Gastroenterol, F-94010 Creteil, France

[9] Ctr Hosp Univ Bordeaux, Serv Gastroenterol, Bordeaux, France

[10] Hop Cochin, Serv Hepatol, F-75674 Paris, France

[11] Ctr Hosp Univ Paul Brousse, Virol Lab, Paris, France

[12] CHU Nantes, Virol Lab, F-44035 Nantes 01, France

[13] CHU Strasbourg, Virol Lab, F-67000 Strasbourg, France

[14] CHU Tours, Virol Lab, Tours, France

[15] Ctr Hepatobiliaire Ctr Hosp Univ, Paris, France

[16] CHU Strasbourg, Serv Gastroenterol, F-67000 Strasbourg, France

[17] CHU Tours, Serv Gastroenterol, Tours, France

[18] CHU Brest, Virol Lab, F-29285 Brest, France

[19] Ctr Hosp Univ Avicenne, Virol Lab, Bobigny, France

[20] Ctr Hosp Univ, Virol Lab, St Etienne, France

[21] CHU Pitie Salpetriere, Virol Lab, Paris, France

[22] CHU Brest, Serv Gastroenterol, F-29285 Brest, France

[23] Ctr Hosp Jean Verdier, Serv Gastroenterol, Bondy, France

[24] Ctr Hosp Univ St Etienne, Serv Gastroenterol, St Etienne, France

[25] CHU Pitie Salpetriere, Serv Gastroenterol, Paris, France

来源：

JOURNAL OF MEDICAL VIROLOGY | 2009年 / 81卷 / 12期

关键词：

HCV subtype; interferon; ribavirin; CHRONIC HEPATITIS-C; ALPHA-2B PLUS RIBAVIRIN; HIV-INFECTED PATIENTS; PEGINTERFERON ALPHA-2B; TREATMENT DURATION; EPIDEMIOLOGIC CHARACTERISTICS; COMBINATION THERAPY; INITIAL TREATMENT; VIRUS GENOTYPE-6; NS5B;

D O I：

10.1002/jmv.21583

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The hepatitis C virus genotype is considered to be the most important baseline predictor of a sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. The influence of the subtype on the sustained virological response was investigated in patients infected with genotypes 1, 4, 5, or 6. This study was done on 597 patients with chronic hepatitis C who were given pegylated interferon and ribavirin for 48 weeks. The overall rate of sustained virological response in the 597 patients was 37.8%. Univariate analysis indicated that the sustained virological response of patients infected with subtype 1b (39%) tended to be higher than that of patients infected with subtype la (30.6%; P=0.06) and it was similar to those patients infected with subtypes 4a (51.3%; P=0.12) or 4d (51.7%; P=0.16). Multivariate analysis indicated that five factors were independently associated with sustained virological response: the age (OR 0.97; 95% CI = 0.95-0.99), absence of cirrhosis (OR: 2.92; 95% CI = 1.7-5.0; P<0.01), absence of HIV co-infection (OR: 2.08; 95% CI = 1.2-3.5; P<0.01), low baseline plasma HCV RNA concentration (OR: 1.74; 95% CI = 1.2-2.6; P< 0.01), and the subtype 1b (OR: 1.61; 95% CI = 1.0-2.5; P=0.04) or subtypes 4a and 4d (OR: 2.03; 95% CI = 1.1-3.8; P=0.03). In conclusion, among difficult-to-treat genotypes, the subtype la is associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d. J. Med. Virol. 81:2029-2035, 2009. (C) 2009 Wiley-Liss, Inc.

引用

页码：2029 / 2035

页数：7

共 36 条

[1] Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5.: A French multicentre retrospective study [J].